vsao Journal Nr. 5 - Oktober 2022

Perspektiven
Abbildung 5. Beginn einer Injektionstherapie.
Literatur
[1] Schweizerische Gesellschaft
für Endokrinologie und Diabetologie,
Hrsg. Empfehlungen der
Schweizerischen Gesellschaft für
Endokrinologie und Diabetologie
(SGED / SSED) für die Behandlung
von Diabetes mellitus Typ 2 (2020)
[Internet]. Baden: SGED SSED; 28.
Februar 2020 [abgerufen am 17.
März 2020]. Verfügbar unter: https://
www.sgedssed.ch/diabetologie/
sged-empfehlungen-diabetologie
[2] Davies MJ, D'Alessio
DA, Fradkin J, Kernan WN,
Mathieu C, Mingrone G, et al.
Management of Hyperglycemia in
Type 2 Diabetes, 2018. A Consensus
Report by the American
Diabetes Association (ADA) and
the European Association for the
Study of Diabetes (EASD). Diabetes
Care. 2018; 41: 2669 – 701.
[3] Nauck MA, Homberger
E, Siegel EG, Allen RC, Eaton RP,
Ebert R, et al. Incretin effects of
increasing glucose loads in man
calculated from venous insulin
and C-peptide responses. J Clin
Endocrinol Metab. 1986; 63 (2):
492 – 8.
[4] Meier JJ, Nauck MA. Is
the diminished incretin effect in
type 2 diabetes just an epi-phenomenon
of impaired beta-cell function?
Diabetes. 2010; 59: 1117 – 25.
[5] Nauck MA, Vardarli
I, Deacon CF, Holst JJ, Meier JJ.
Secretion of glucagon-like peptide-1
(GLP-1) in type 2 diabetes:
what is up, what is down? Diabetologia.
2011; 54: 10 – 8.
[6] Montvida O, Green JB,
Atherton J, Paul SK. Treatment
with incretins does not increase
the risk of pancreatic diseases
compared to older anti-hyperglycaemic
drugs, when added to
metformin: real world evidence
in people with Type 2 diabetes.
Diabet Med. 2019; 36: 491 – 8.
[7] Kim Y-G, Kim S, Han SJ,
Kim DJ, Lee K-W, Kim HJ. Dipeptidyl
Peptidase-4 Inhibitors and
the Risk of Pancreatitis in Patients
with Type 2 Diabetes Mellitus: A
Population-Based Cohort Study. J
Diabetes Res. 2018; 2018: 5246976.
[8] Packer M. Do DPP-4
Inhibitors Cause Heart Failure
Events by Promoting Adrenergically
Mediated Cardiotoxicity?
Clues From Laboratory Models and
Clinical Trials. Circ Res. 2018; 122:
928 – 32.
[9] Nauck MA, Kahle M, Baranov
O, Deacon CF, Holst JJ. Addition
of a dipeptidyl peptidase-4
inhibitor, sitagliptin, to ongoing
therapy with the glucagon-like
peptide-1 receptor agonist liraglutide:
A randomized controlled trial
in patients with type 2 diabetes.
Diabetes Obes Metab. 2017; 19:
200 – 7.
[10] Baggio LL, Drucker DJ.
Glucagon-like peptide-1 receptors
in the brain: controlling food
intake and body weight. J Clin
Invest. 2014; 124: 4223 – 6.
[11] Lund A, Knop FK,
Vilsbøll T. Glucagon-like peptide-1
receptor agonists for the treatment
of type 2 diabetes: differences and
similarities. Eur J Intern Med.
2014; 25: 407 – 14.
[12] Zelniker TA, Braunwald
E. Cardiac and Renal Effects of
Sodium-Glucose Co-Transporter
2 Inhibitors in Diabetes: JACC
State-of-the-Art Review. J Am Coll
Cardiol. 2018; 72: 1845 – 55.
[13] Fioretto P, Zambon A,
Rossato M, Busetto L, Vettor R.
SGLT2 Inhibitors and the Diabetic
Kidney. Diabetes Care. 2016; 39
Suppl 2: S165 – 71.
[14] Wanner C, Inzucchi
SE, Lachin JM, Fitchett D, von
Eynatten M, Mattheus M, et al.
Empagliflozin and Progression of
Kidney Disease in Type 2 Diabetes.
N Engl J Med. 2016; 375: 323 – 34.
[15] Perkovic V, Jardine MJ,
Neal B, Bompoint S, Heerspink
HJL, Charytan DM, et al. Canagliflozin
and Renal Outcomes in Type
2 Diabetes and Nephropathy. N
Engl J Med. 2019; 380: 2295 – 306.
[16] Zinman B, Wanner C,
Lachin JM, Fitchett D, Bluhmki
E, Hantel S, et al. Empagliflozin,
Cardiovascular Outcomes, and
Mortality in Type 2 Diabetes. N
Engl J Med. 2015; 373: 2117 – 28.
[17] Neal B, Perkovic V,
Mahaffey KW, de Zeeuw D, Fulcher
G, Erondu N, et al. Canagliflozin
and Cardiovascular and Renal
Events in Type 2 Diabetes. N Engl J
Med. 2017; 377: 644 – 57.
[18] Wiviott SD, Raz I,
Bonaca MP, Mosenzon O, Kato ET,
Cahn A, et al. Dapagliflozin and
Cardiovascular Outcomes in Type
2 Diabetes. N Engl J Med. 2019;
380: 347 – 57.
vsao /asmac Journal 5/22 37